Effect of the Nrf2‑ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma

  • Authors:
    • Shiliang Ji
    • Yufeng Xiong
    • Xingxing Zhao
    • Yanli Liu
    • Li Qiang Yu
  • View Affiliations

  • Published online on: March 18, 2019     https://doi.org/10.3892/ol.2019.10156
  • Pages: 5175-5186
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to examine the effects of the nuclear factor erythroid‑2 related factor 2‑antioxidant‑responsive element (Nrf2‑ARE) signaling pathway on the biological characteristics and sensitivity to targeted therapy in human renal cell carcinoma (RCC) cells. RCC tissues and adjacent tissues were collected and assessed by immunohistochemistry to determine the expression of Nrf2, NAD(P)H dehydrogenase [quinone] 1 (NQO1) and heme oxygenase‑1 (HO‑1) to analyze the clinicopathological features of RCC. A series of in vitro experiments were conducted to analyze the biological characteristics of Nrf2‑ARE signaling in RCC. The renal cancer cell line, 786‑0 was used, and cells was divided into a mock group, negative control group and small hairpin (sh)RNA‑Nrf2 group. A Cell Counting Kit‑8 assay was performed alongside flow cytometry to detect cell viability, cell cycle stage and apoptosis following treatment with sunitinib. The results demonstrated that Nrf2, NQO1 and HO‑1 were significantly upregulated in RCC tissues compared with adjacent tissues and were associated with tumor node metastasis stage, Fuhrman classification and lymph node metastasis. Following shRNA‑Nrf2 transfection, the 786‑0 cells demonstrated a significant decrease in viability, cell invasion and scratch healing rate, and the mRNA and protein expression levels of Nrf2, NQO1, HO‑1 and glutathione transferase were significantly decreased, which enhanced the sensitivity to sunitinib, arrested cells in the G0/G1 phase and increased apoptosis. In conclusion, Nrf2‑ARE signaling is important for RCC progression, and its inhibition may increase sensitivity to targeted drugs to provide novel developments for RCC treatment.

References

1 

Lipworth L, Tarone RE and McLaughlin JK: The epidemiology of renal cell carcinoma. J Urol. 176:2353–2358. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Zheng B, Zhu H, Gu D, Pan X, Qian L, Xue B, Yang D, Zhou J and Shan Y: MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 459:234–239. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Breau RH and Blute ML: Surgery for renal cell carcinoma metastases. Curr Opin Urol. 20:375–381. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Bukowski RM: Systemic therapy for metastatic renal cell carcinoma in treatment naive patients: A risk-based approach. Expert Opin Pharmacother. 11:2351–2362. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, et al: Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 13:151–159. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Achermann C, Stenner F and Rothschild SI: Treatment, outcome and prognostic factors in renal cell carcinoma-A single center study (2000–2010). J Cancer. 7:921–927. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN and Stief CG: Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy? Eur Urol. 61:307–316. 2012. View Article : Google Scholar : PubMed/NCBI

9 

M Eel D: Utilization of sunitinib for renal cell cancer: An egyptian university hospital experience. Asian Pac J Cancer Prev. 17:3161–3166. 2016.PubMed/NCBI

10 

Zheng WX, Yan F, Xue Q, Wu GJ, Qin WJ, Wang FL, Qin J, Tian CJ and Yuan JL: Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. Onco Targets Ther. 8:2081–2088. 2015.PubMed/NCBI

11 

Rini BI and Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Buczek M, Escudier B, Bartnik E, Szczylik C and Czarnecka A: Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. Biochim Biophys Acta. 1845:31–41. 2014.PubMed/NCBI

13 

Jaramillo MC and Zhang DD: The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Magesh S, Chen Y and Hu L: Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 32:687–726. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP, Kraft AD, Lee JM, Li J and Johnson J: The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal. 11:497–508. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N and Jiang T: Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 8:e634042013. View Article : Google Scholar : PubMed/NCBI

17 

Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y and Kwak M: NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 71:2260–2275. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Samatiwat P, Prawan A, Senggunprai L and Kukongviriyapan V: Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn Schmiedebergs Arch Pharmacol. 388:601–612. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A and Morel F: Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer. 45:2219–2227. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Muglia VF and Prando A: Renal cell carcinoma: Histological classification and correlation with imaging findings. Radiol Bras. 48:166–174. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T and Wild PJ: Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 56:636–643. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL and Fox SB: BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res. 13:467–474. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT and Furge KA: CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 73:2044–2051. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Gu S, Lai Y, Chen H, Liu Y and Zhang Z: miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep. 7:121552017. View Article : Google Scholar : PubMed/NCBI

26 

Lu MC, Ji JA, Jiang ZY and You QD: The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: An update. Med Res Rev. 36:924–963. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Liu D, Duan X, Dong D, Bai C, Li X, Sun G and Li B: Activation of the Nrf2 pathway by inorganic arsenic in human hepatocytes and the role of transcriptional repressor Bach1. Oxid Med Cell Longev. 2013:9845462013. View Article : Google Scholar : PubMed/NCBI

28 

Deng C, Tao R, Yu SZ and Jin H: Inhibition of 6-hydroxydopamine-induced endoplasmic reticulum stress by sulforaphane through the activation of Nrf2 nuclear translocation. Mol Med Rep. 6:215–219. 2012.PubMed/NCBI

29 

Ildefonso CJ, Jaime H, Brown EE, Iwata RL, Ahmed CM, Massengill MT, Biswal MR, Boye SE, Hauswirth WW, Ash JD, et al: Targeting the Nrf2 signaling pathway in the retina with a gene-delivered secretable and cell-penetrating peptide. Invest Ophthalmol Vis Sci. 57:372–386. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Wan Hasan WN, Kwak MK, Makpol S, Wan Ngah WZ and Mohd Yusof YA: Piper betle induces phase I & II genes through Nrf2/ARE signaling pathway in mouse embryonic fibroblasts derived from wild type and Nrf2 knockout cells. BMC Complement Altern Med. 14:722014. View Article : Google Scholar : PubMed/NCBI

31 

Hayes JD and McMahon M: NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Geismann C, Arlt A, Sebens S and Schäfer H: Cytoprotection ‘gone astray’: Nrf2 and its role in cancer. Onco Targets Ther. 7:1497–1518. 2014.PubMed/NCBI

33 

Yoo NJ, Kim YR and Lee SH: Expression of NRF2, a cytoprotective protein, in gastric carcinomas. APMIS. 118:613–614. 2010.PubMed/NCBI

34 

Ji L, Wei Y, Jiang T and Wang S: Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int J Clin Exp Pathol. 7:1124–1131. 2014.PubMed/NCBI

35 

Wang J, Zhang M, Zhang L, Cai H, Zhou S, Zhang J and Wang Y: Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J Surg Res. 164:e99–e105. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Kim WD, Kim YW, Cho IJ, Lee CH and Kim SG: E-cadherin inhibits nuclear accumulation of Nrf2: Implications for chemoresistance of cancer cells. J Cell Sci. 125:1284–1295. 2012. View Article : Google Scholar : PubMed/NCBI

38 

Niture SK and Jaiswal AK: Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI

39 

Rotblat B, Melino G and Knight RA: NRF2 and p53: Januses in cancer? Oncotarget. 3:1272–1283. 2012. View Article : Google Scholar : PubMed/NCBI

40 

Zhang M, An C, Gao Y, Leak RK, Chen J and Zhang F: Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol. 100:30–47. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Aborode FA, Raab A, Voigt M, Costa LM, Krupp EM and Feldmann J: The importance of glutathione and phytochelatins on the selenite and arsenate detoxification in Arabidopsis thaliana. J Environ Sci (China). 49:150–161. 2016. View Article : Google Scholar : PubMed/NCBI

42 

Niture SK, Kaspar JW, Shen J and Jaiswal AK: Nrf2 signaling and cell survival. Toxicol Appl Pharmacol. 244:37–42. 2010. View Article : Google Scholar : PubMed/NCBI

43 

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI

44 

Mitsuishi Y, Taguchi K, Kawatani Y, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ and Calhoun ES: Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 22:66–79. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Zhong Y, Zhang F, Sun Z, Zhou W, Li ZY, You QD, Guo QL and Hu R: Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol Carcinog. 52:824–834. 2013.PubMed/NCBI

46 

Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, Park C, Youn MJ, So HS and Park R: Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer. 60:47–56. 2008. View Article : Google Scholar : PubMed/NCBI

47 

Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, Schreiber S and Schäfer H: Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 32:4825–4835. 2013. View Article : Google Scholar : PubMed/NCBI

48 

Li QK, Singh A, Biswal S, Askin F and Gabrielson E: KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet. 56:230–234. 2011. View Article : Google Scholar : PubMed/NCBI

49 

Lim JH, Kim KM, Kim SW, Hwang O and Choi HJ: Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. Pharmacol Res. 57:325–331. 2008. View Article : Google Scholar : PubMed/NCBI

50 

Zhang Y, Guan L, Wang X, Wen T, Xing J and Zhao J: Protection of chlorophyllin against oxidative damage by inducing HO-1 and NQO1 expression mediated by PI3K/Akt and Nrf2. Free Radic Res. 42:362–371. 2008. View Article : Google Scholar : PubMed/NCBI

51 

Mayer IA and Arteaga CL: The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 67:11–28. 2016. View Article : Google Scholar : PubMed/NCBI

52 

Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI

53 

West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI

54 

Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG and Kolenko VM: Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther. 11:1510–1517. 2012. View Article : Google Scholar : PubMed/NCBI

55 

Chen YL, Ge GJ, Qi C, Wang H, Wang HL, Li LY, Li GH and Xia LQ: A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma. J Cell Physiol. 233:6649–6660. 2018. View Article : Google Scholar : PubMed/NCBI

56 

Imbulgoda A, Heng DY and Kollmannsberger C: Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res. 201:165–184. 2014. View Article : Google Scholar : PubMed/NCBI

57 

Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F and Procopio G: Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Ther Adv Urol. 7:59–68. 2015. View Article : Google Scholar : PubMed/NCBI

58 

Yang F, Jove V, Xin H, Hedvat M, Van Meter TE and Yu H: Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res. 8:35–45. 2010. View Article : Google Scholar : PubMed/NCBI

59 

Deng X, Rui W, Zhang F and Ding W: PM2.5 induces Nrf2-mediated defense mechanisms against oxidative stress by activating PIK3/AKT signaling pathway in human lung alveolar epithelial A549 cells. Cell Biol Toxicol. 29:143–157. 2013. View Article : Google Scholar : PubMed/NCBI

60 

Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ji, S., Xiong, Y., Zhao, X., Liu, Y., & Yu, L.Q. (2019). Effect of the Nrf2‑ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma. Oncology Letters, 17, 5175-5186. https://doi.org/10.3892/ol.2019.10156
MLA
Ji, S., Xiong, Y., Zhao, X., Liu, Y., Yu, L. Q."Effect of the Nrf2‑ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma". Oncology Letters 17.6 (2019): 5175-5186.
Chicago
Ji, S., Xiong, Y., Zhao, X., Liu, Y., Yu, L. Q."Effect of the Nrf2‑ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma". Oncology Letters 17, no. 6 (2019): 5175-5186. https://doi.org/10.3892/ol.2019.10156